NICE's managed access deal for Spinraza could signal more flexibility on orphan drugs

Spinal muscular atrophy patients in England and Wales can now begin to access Spinraza nusinersen after NICE reached a deal with Biogen to provide the drug through a managed access program.

NHS England will begin funding Spinraza treatment for a five-year term and will also collect data on

Read the full 475 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE